Protara Therapeutics (TARA) lost ~22% on Tuesday after the company posted updated interim data from a mid-stage trial for its lead candidate TARA-002 in patients with non-muscle invasive bladder ...
The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...
Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small ...
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference ...
Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...
Staying fit and active has long been associated with better heart and overall health. It might also improve the chances of survival for people with some forms of cancer. A study published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results